Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α 1 ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( VATON Study)

Key Result

Vibegron add-on therapy to α1-blockers improved persistent overactive bladder symptoms in benign prostatic hyperplasia patients safely and effectively.

Key Points

• The aim is to evaluate the efficacy and safety of vibegron as an add-on therapy for patients with benign prostatic hyperplasia (BPH) experiencing persistent overactive bladder (OAB) symptoms.
• Conducted as a multi-center prospective randomized controlled trial
• Included patients with BPH and persistent OAB symptoms
• Administered vibegron in addition to α1-blocker treatment
• Vibegron therapy was associated with a reduction in OAB symptoms
• The safety profile was found to be acceptable among participants
• Significant improvements were noted compared to the control group receiving only α1-blocker